Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Defining therapeutic chimerism thresholds for comprehensive sickle cell disease correction in the townes mouse model

View Full Paper
Ask AI
Bookmark
Share

Authors

DDDeAnna DiazFCFrançois Christen

Discussion

Loading...

Member takes

Overview

Observational analysis uncovered significant improvement in sickle cell disease pathology with hematopoietic stem cells, indicating a minimum chimerism level for effective treatment.

Key Points

  • Mixed hematopoietic chimerism as low as 2–3% significantly reduced sickle red blood cell proportions.
  • Chimerism levels of 10–30% abolished sickling red blood cells, improving multiple SCD complications.
  • Analysis in the Townes mouse model utilized mixed donor HSCs and assessed hematopoietic activity post-transplantation.
  • Findings may inform gene therapies by clarifying chimerism's role in alleviating sickle cell disease symptoms.

Cite This Study

Diaz et al. (2025) studied this question.

synapsesocial.com/papers/69362f5a4fa91c937236daebhttps://doi.org/10.1182/blood-2025-4700
View Full Paper
Ask AI
Bookmark
Share